Background: The growth hormone receptor (GHR) was the first class 1 cytokine receptor to be cloned, and it has been studied intensively. The crystal structures of the bound and unbound forms have been solved and the energetic contributions of residues involved in the binding interaction have been quantified. Two receptor subunits bind to opposite sides of the hormone through site 1 and site 2, and a third interaction occurs between receptors in the lower β-sandwich module at site 3. All three interactions are required for receptor activation, which was thought to be a consequence of hormone-induced receptor dimerization. However, substantial data support the existence of a constitutive receptor dimer that interacts via the transmembrane domain (TMD), with receptor activation triggered by a hormone-induced conformational change. Mutagenesis studies and crystal structure data indicate that receptor activation involves a relative rotation and scissor movement of subunits to activate the associated tyrosine kinase, Janus kinase 2 (JAK2). We have recently reported that a second tyrosine kinase, an Src-family kinase, also associates constitutively with the receptor and activates the Ras–extracellular-signal-regulated kinase pathway. Activation of this kinase requires a conformational change in a loop of the lower sandwich module, and a different orientation of the TMDs than needed for JAK2 activation. Conclusions: This structural difference could allow differential activation of these two kinases by GH analogues such as I179M human GH.

1.
Lanning NJ, Carter-Su C: Recent advances in growth hormone signalling. Rev Endocr Metab Disord 2006;7:225–235.
[PubMed]
2.
Lichanska AM, Waters MJ: How GH controls growth, obesity and sexual dimorphism. Trends Genet 2008;24:41–47.
[PubMed]
3.
Clackson T, Ultsch MH, Wells JA, deVos AM: Structural and functional analysis of the 1:1 GH:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 1998;277:1111–1128.
4.
Walsh STR, Jevitts LM, Sylvester JE, Kossiakoff AA: Site2 binding energetics of the regulatory step of GH-induced receptor homodimerization. Protein Sci 2003;12:1960–1970.
5.
Bernat B, Pal G, Sun M, Kossiakoff AA: Determination of the energetics governing the regulatory step in GH-induced receptor homodimerization. Proc Natl Acad Sci USA 2003;100:952–957.
6.
Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA: Rational design of potent antagonists to the human GH receptor. Science 1992;256:1677–1680.
[PubMed]
7.
Rowlinson SW, Behncken SN, Rowland JE, Clarkson RW, Strasberg CJ, Wu Z, Baumbach W, Waters MJ: Activation of chimeric and full length GH receptor by GH receptor monoclonal antibodies. A specific conformational change may be required for full length receptor signalling. J Biol Chem 1998;273:5307–5314.
[PubMed]
8.
Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK: Binding and functional studies with the GH receptor antagonist, B2036PEG (pegvisomant) reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 2001;86:1716–1723.
[PubMed]
9.
Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ: Ligand-independent GH receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA 2002;99:9858–9863.
[PubMed]
10.
van Kerkhof P, Smeets M, Strous GJ: The ubiquitin-proteasome pathway regulates the availability of the GH receptor. Endocrinology 2002;143:1243–1252.
11.
Brown RJ, Adams JJ, Pelekanos RR, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ: Model for GH receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12:814–821.
[PubMed]
12.
Chen C, Brinkworth R, Waters MJ: The role of receptor dimerization domain residues in GH signalling. J Biol Chem 1997;272:5133–5140.
[PubMed]
13.
Gent J, Vanden Eijnden M, van Kerkhof P, Strous GJ: Dimerization and signal transduction of the GH receptor. Mol Endocrinol 2003;17:967–975.
[PubMed]
14.
Wan Y, Zheng YZ, Harris JM, Brown R, Waters MJ: Epitope map for a GH receptor agonist monoclonal antibody, MAb 263. Mol Endocrinol 2003;17:2240–2250.
15.
Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, Millard K, Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ: An agonist-induced conformational change in the GH receptor determines the choice of signalling pathway. Nat Cell Biol 2008;10:740–747.
[PubMed]
16.
Lewis MD, Horan M, Millar DS, Newsway V, Easter TE, Fryklund L, Gregory JW, Norin M, Del Valle CJ, López-Siguero JP, Cañete R, López-Canti LF, Díaz-Torrado N, Espino R, Ulied A, Scanlon MF, Procter AM, Cooper DN: A novel dysfunctional GH variant (Ile179Met) exhibits a decreased ability to activate the ERK pathway. J Clin Endocrinol Metab 2004;89:1068–1075.
[PubMed]
17.
Thompson BJ, Shang CA, Waters MJ: Identification of genes induced by GH in liver using cDNA arrays. Endocrinology 2000;141:4321–4324.
[PubMed]
You do not currently have access to this content.